- £139.30m
- £232.88m
- £19.94m
- 34
- 52
- 25
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.39 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | 6.38% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.49 | ||
| Price to Tang. Book | 0.49 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.99 | ||
| EV to EBITDA | 27.15 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.68% | ||
| Return on Equity | -7.2% | ||
| Operating Margin | -73.16% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | 0.53 | 15.71 | 19.94 | 17.52 | 21.45 | 512.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +33.33 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Life Science REIT plc is a United Kingdom-based closed-ended real estate investment trust. The Company seeks to invests in a diversified portfolio of properties across the United Kingdom, which are typically leased or intended to be leased to tenants operating in, or providing a benefit to, the life science sector. It acquires or develops properties, such as wet and dry laboratories, offices, incubators and co-working space, manufacturing and testing facilities and data centers. It retains flexibility to acquire individual buildings, a group of buildings across a single science park or the entirety of a science park. This may include purchasing or developing buildings that are leased or intended to be leased to tenants providing ancillary services to employees of companies operating in or providing a benefit to, the life science sector. Its investment adviser is Ironstone Asset Management Limited.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 27th, 2021
- Public Since
- November 19th, 2021
- Sector
- Residential & Commercial REITs
- Industry
- Financials
- Exchange
London Stock Exchange- Shares in Issue
- 350,000,000
- Address
- 55 Wells Street, LONDON, W1T 3PT
- Web
- https://lifesciencereit.co.uk/
- Phone
- +44 1392477500
- Auditors
- Deloitte LLP
Latest News for LABS
Upcoming Events for LABS
Similar to LABS
abrdn Property Income Trust
London Stock Exchange
Aew UK Reit
London Stock Exchange
Alina Holdings
London Stock Exchange
Alternative Income REIT
London Stock Exchange
Assura
London Stock Exchange
FAQ
As of Today at 19:13 UTC, shares in Life Science Reit are trading at 39.80p. This share price information is delayed by 15 minutes.
Shares in Life Science Reit last closed at 39.80p and the price had moved by -43.94% over the past 365 days. In terms of relative price strength the Life Science Reit share price has underperformed the FTSE All Share Index by -46.79% over the past year.
The overall consensus recommendation for Life Science Reit is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Life Science Reit dividend yield is 5.03% based on the trailing twelve month period.
Last year, Life Science Reit paid a total dividend of £0.02, and it currently has a trailing dividend yield of 5.03%.Looking ahead, the next dividend pay date is 2024-05-13.
We do not have data on when Life Science Reit is to next pay dividends. The historic dividend yield on Life Science Reit shares is currently 5.03%.
To buy shares in Life Science Reit you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 39.80p, shares in Life Science Reit had a market capitalisation of £139.30m.
Here are the trading details for Life Science Reit:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: LABS
Based on an overall assessment of its quality, value and momentum Life Science Reit is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Life Science Reit is 59.91p. That is 50.54% above the last closing price of 39.80p.
Analysts covering Life Science Reit currently have a consensus Earnings Per Share (EPS) forecast of £0.02 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Life Science Reit. Over the past six months, its share price has underperformed the FTSE All Share Index by -46.4%.
As of the last closing price of 39.80p, shares in Life Science Reit were trading -31.04% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Life Science Reit PE ratio based on its reported earnings over the past 12 months is 17.39. The shares last closed at 39.80p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Life Science Reit's directors